Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PLRX

Pliant Therapeutics (PLRX)

Pliant Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PLRX
DateTimeSourceHeadlineSymbolCompany
01/02/20257:00AMGlobeNewswire Inc.Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PLRXPliant Therapeutics Inc
11/21/20247:00AMGlobeNewswire Inc.Pliant Therapeutics to Participate in Upcoming Investor EventsNASDAQ:PLRXPliant Therapeutics Inc
11/18/20245:00PMGlobeNewswire Inc.Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024NASDAQ:PLRXPliant Therapeutics Inc
11/14/20244:05PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:PLRXPliant Therapeutics Inc
11/07/20243:17PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PLRXPliant Therapeutics Inc
11/07/20243:14PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLRXPliant Therapeutics Inc
11/07/20243:05PMGlobeNewswire Inc.Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:PLRXPliant Therapeutics Inc
11/06/20247:00AMGlobeNewswire Inc.Pliant Therapeutics to Participate in the Stifel Healthcare ConferenceNASDAQ:PLRXPliant Therapeutics Inc
10/17/20247:00AMGlobeNewswire Inc.Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024NASDAQ:PLRXPliant Therapeutics Inc
10/04/20244:34PMEdgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:PLRXPliant Therapeutics Inc
10/01/20243:35PMGlobeNewswire Inc.Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical AffairsNASDAQ:PLRXPliant Therapeutics Inc
09/30/20243:45PMGlobeNewswire Inc.Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PLRXPliant Therapeutics Inc
09/27/20243:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLRXPliant Therapeutics Inc
09/24/20247:00AMGlobeNewswire Inc.Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical OfficerNASDAQ:PLRXPliant Therapeutics Inc
09/10/20247:00AMGlobeNewswire Inc.Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024NASDAQ:PLRXPliant Therapeutics Inc
08/28/20247:00AMGlobeNewswire Inc.Pliant Therapeutics to Participate in Upcoming Investor EventsNASDAQ:PLRXPliant Therapeutics Inc
08/28/20247:00AMGlobeNewswire Inc.Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of DirectorsNASDAQ:PLRXPliant Therapeutics Inc
08/26/20248:10AMGlobeNewswire Inc.Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024NASDAQ:PLRXPliant Therapeutics Inc
08/07/20243:13PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PLRXPliant Therapeutics Inc
08/07/20243:08PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLRXPliant Therapeutics Inc
08/07/20243:05PMGlobeNewswire Inc.Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:PLRXPliant Therapeutics Inc
08/06/20243:03PMGlobeNewswire Inc.Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:PLRXPliant Therapeutics Inc
07/15/202410:54AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PLRXPliant Therapeutics Inc
07/15/20247:00AMGlobeNewswire Inc.Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple MeasuresNASDAQ:PLRXPliant Therapeutics Inc
07/12/20245:37PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PLRXPliant Therapeutics Inc
07/12/20245:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PLRXPliant Therapeutics Inc
07/12/20245:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PLRXPliant Therapeutics Inc
07/11/20243:54PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PLRXPliant Therapeutics Inc
07/11/20243:47PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PLRXPliant Therapeutics Inc
07/11/20243:41PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PLRXPliant Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PLRX